Subscribe
Piotr Swat / Shutterstock.com
19 June 2025NewsAmericasMarisa Woutersen

Biotech seeks to stop Kirkland from representing rival in Eylea dispute

Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing effective screening measures.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USITC to investigate potential section 337 breach in trade secrets case
7 February 2023   Viking alleges Chinese competitor stole information relating to metabolic disorders drug.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.


Editor's picks

Diverging in the detail: UPC local divisions and Court of Appeal take different paths
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

Editor's picks

Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

More on this story

Americas
USITC to investigate potential section 337 breach in trade secrets case
7 February 2023   Viking alleges Chinese competitor stole information relating to metabolic disorders drug.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

More on this story

Americas
USITC to investigate potential section 337 breach in trade secrets case
7 February 2023   Viking alleges Chinese competitor stole information relating to metabolic disorders drug.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

More features

Regeneron hits Amgen over its blockbuster eye disease treatment
Japanese firm adds ex-Norvartis and Alnylam in-house counsel
UPC confirms permanent injunction against Curio in 10x tech dispute
Novo Nordisk patent lapse opens door for Canadian Ozempic generics
McDermott Will & Emery appoints senior Paris litigator
UK govt sets sights on being AI drug discovery ‘world leader’
UPC promises CMS overhaul with new phased release
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'